Clinuvel Pharmaceuticals Ltd
ASX:CUV

Watchlist Manager
Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Watchlist
Price: 12.33 AUD 1.4% Market Closed
Market Cap: 619m AUD

Intrinsic Value

The intrinsic value of one CUV stock under the Base Case scenario is hidden AUD. Compared to the current market price of 12.33 AUD, Clinuvel Pharmaceuticals Ltd is hidden .

The Intrinsic Value is calculated as the average of DCF and Relative values:

CUV Intrinsic Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation History
Clinuvel Pharmaceuticals Ltd

Intrinsic Value History
Dive into the past to invest in the future

CUV looks undervalued. But is it really? Some stocks live permanently below intrinsic value; one glance at Historical Valuation reveals if CUV is one of them.

Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Show Historical Valuation
What is Valuation History?
Ask AI Assistant
What other research platforms think about CUV?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is CUV valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Clinuvel Pharmaceuticals Ltd.

Explain Valuation
Compare CUV to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

A heavy reliance on SCENESSE revenue leaves Clinuvel vulnerable to market fluctuations and potential challenges such as payer reimbursement cuts or increased competition targeting EPP treatments.

Bull Theses

Clinuvel’s proprietary SCENESSE therapy has a first-mover advantage in treating EPP, with demonstrated clinical efficacy and expanding regulatory approvals laying a solid foundation for revenue growth.

Show More Less
How do you feel about CUV?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Clinuvel Pharmaceuticals Ltd

Current Assets 263m
Cash & Short-Term Investments 224.1m
Receivables 27.5m
Other Current Assets 11.4m
Non-Current Assets 8.8m
PP&E 7.1m
Intangibles 185k
Other Non-Current Assets 1.5m
Current Liabilities 27.2m
Accounts Payable 9.9m
Other Current Liabilities 17.3m
Non-Current Liabilities 3.7m
Long-Term Debt 97.3k
Other Non-Current Liabilities 3.6m
Efficiency

Free Cash Flow Analysis
Clinuvel Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Clinuvel Pharmaceuticals Ltd

Revenue
95m AUD
Cost of Revenue
-1.8m AUD
Gross Profit
93.2m AUD
Operating Expenses
-47.5m AUD
Operating Income
45.7m AUD
Other Expenses
-9.6m AUD
Net Income
36.2m AUD
Fundamental Scores

CUV Profitability Score
Profitability Due Diligence

Clinuvel Pharmaceuticals Ltd's profitability score is hidden . The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROIC
Exceptional ROIC
Exceptional Operating Margin
Exceptional Gross Margin
hidden
Profitability
Score

Clinuvel Pharmaceuticals Ltd's profitability score is hidden . The higher the profitability score, the more profitable the company is.

CUV Solvency Score
Solvency Due Diligence

Clinuvel Pharmaceuticals Ltd's solvency score is hidden . The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
hidden
Solvency
Score

Clinuvel Pharmaceuticals Ltd's solvency score is hidden . The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CUV Price Targets Summary
Clinuvel Pharmaceuticals Ltd

Wall Street analysts forecast CUV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CUV is 26.26 AUD with a low forecast of 14.14 AUD and a high forecast of 43.94 AUD.

Lowest
Price Target
14.14 AUD
15% Upside
Average
Price Target
26.26 AUD
113% Upside
Highest
Price Target
43.94 AUD
256% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for CUV is hidden .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
HIDDEN
Show
Dividend Yield
Lowest
Average
Highest
Buyback Yield
HIDDEN
Debt Paydown Yield
HIDDEN

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one CUV stock?

The intrinsic value of one CUV stock under the Base Case scenario is hidden AUD.

Is CUV stock undervalued or overvalued?

Compared to the current market price of 12.33 AUD, Clinuvel Pharmaceuticals Ltd is hidden .

Back to Top